Physician profile
Anu Duvoor
NPI 1528089497
$5,850.85
in general payments reported to CMS, 2019-2025
45 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $399 · 2021: $652 · 2022: $1,245 · 2023: $1,207 · 2024: $912 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $758.72 | 2019-2025 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $455.34 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $451.24 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $379.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $333.88 | 2021-2024 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $234.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $212.47 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.66 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $180.09 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $178.15 | 2019-2025 | Eliquis |
| Lilly USA, LLC | $177.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $164.68 | 2019-2025 | Jynarque, Voyxact, Nuedexta |
| Travere Therapeutics, INC. | $162.80 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $161.29 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $154.16 | 2019-2023 | Velphoro, Korsuva |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $148.83 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.40 | 2022-2025 | Xifaxan |
| Aurinia Pharma U.S., INC. | $122.72 | 2021-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $122.62 | 2020-2023 | Gattex |
| Mallinckrodt Hospital Products INC. | $121.76 | 2020-2025 | Acthar |
| Abbott Laboratories | $114.95 | 2021-2022 | |
| Astellas Pharma US INC | $104.04 | 2023-2025 | Veozah, Myrbetriq |
| Genzyme Corporation | $96.30 | 2019-2023 | |
| Horizon Therapeutics Plc | $67.65 | 2022-2023 | Krystexxa |
| Vifor Pharma, INC. | $62.68 | 2020-2023 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $59.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.59 | 2024-2025 | |
| Exact Sciences Corporation | $50.77 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $44.07 | 2023-2025 | Keveyis |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.92 | 2022 | |
| Insulet Corporation | $36.48 | 2020-2022 | |
| Bardy Diagnostics, INC. | $35.47 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $33.78 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $26.00 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $23.89 | 2025 | Skyclarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.16 | 2022 | |
| Merck Sharp & Dohme LLC | $19.44 | 2023 | Verquvo |
| Dexcom, INC. | $17.62 | 2021 | |
| Ardelyx, INC. | $16.96 | 2024 | Ibsrela |
| Actelion Pharmaceuticals US, INC. | $16.52 | 2024 | Opsumit, Uptravi |
| Pharmacosmos Therapeutics INC. | $15.16 | 2024 | Monoferric |
| Ultragenyx Pharmaceutical INC. | $14.41 | 2020 | |
| Stryker Corporation | $14.13 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amarin Pharma, INC. | $12.80 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Duvoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.